Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05225077
  4. Details
NCT05225077 Clinical Trial

Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients

Percutaneous Coronary Intervention Clinical Trial

Official title:
Effect of Short-term Dapagliflozin on Renal Function After Heart Catheterization or Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05225077
Other study ID # PROTECT-CKD
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 1, 2022
Est. completion date December 31, 2023

Study information
Verified date January 2022
Source Dong-A University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as observed the incidence of CIN.

Recruitment information / eligibility
Status Recruiting
Enrollment 600
Est. completion date December 31, 2023
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria: - Age>18 years - Written informed consent - Glomerular Filtration Rate (GFR)= 30 ml/min/1.73m2 [CKD stage G1-G3] - Percutaneous coronary intervention in patients with NSTEMI, UA, STCD and asymptomatic patients Exclusion Criteria: - Active malignancy - Class I or equivalent indication for treatment with a SGLT2 inhibitor - Pregnancy or willing of pregnancy during the follow up period - Active urogenital infection - Diabetes mellitus type 1 - History of diabetic ketoacidosis - Cardiogenic shock - eGFR < 29 ml/min/1.73m2

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Dapagliflozin 10 MG [Farxiga]
Dapagliflozin 10 mg once a day for 1 month after CAG or PCI.

Locations
Country Name City State
Korea, Republic of Dong A University Hospital Busan

Sponsors (1)
Lead Sponsor Collaborator
Dong-A University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Incidence of contrast induced nephropathy Serum creatinine (Scr) elevation of >25% or >0.5 mg/dl (44 µmol/l) from baseline within 48 hours 48 hours
See also
  Status Clinical Trial Phase
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Not yet recruiting NCT05669222 - The FAVOR V AMI Trial N/A
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05240781 - Zotarolimus vs Sirolimus Eluting Stent in High Bleeding Risk N/A
Recruiting NCT03378934 - Anti-platelet Effect of Berberine in Patients After Percutaneous Coronary Intervention Phase 4
Not yet recruiting NCT06025071 - Residual Inflammatory Risk-Guided colcHicine in Elderly Trial Phase 4
Withdrawn NCT04043091 - Coronary Angiography in Critically Ill Patients With Type II Myocardial Infarction N/A
Completed NCT03085823 - The All-comers Sirolimus-coated Balloon European Registry
Completed NCT02837744 - Studying Hemostatic Effect of Axiostat® Dressing on Radial Access After Percutaneous Procedure
Completed NCT02044146 - A Pharmacodynamic Study of a Personalized Strategy for P2Y12 Inhibition Versus Ticagrelor in Reducing Ischemic and Bleeding Risk Phase 2/Phase 3
Completed NCT03131271 - Effect of Ice Bag Application to Femoral Region on Pain in Patients Undergoing Percutaneous Coronary Intervention N/A
Completed NCT01135667 - Prasugrel Versus Double Dose Clopidogrel to Treat Clopidogrel Low-responsiveness After PCI Phase 4
Completed NCT01156571 - A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX) Phase 3
Unknown status NCT00751491 - Clopidogrel Versus Adenosin in Non Urgent Percutaneous Coronary Intervention (PCI) Phase 3
Completed NCT00725868 - Blood Endothelium Biomarkers to Predict Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention N/A
Completed NCT03708588 - Chewed Versus Integral Pill of Ticagrelor Phase 4
Completed NCT04163393 - R-One Efficiency For PCI Evolution With Robotic Assistance N/A
Recruiting NCT05554588 - Intrathrombus Thrombolysis Versus Aspiration Thrombectomy During Primary PCI N/A
Recruiting NCT06080919 - Plaque Modification And Impact On Microcirculatory Territory After Drug-Coated Balloon Percutaneous Coronary Intervention (PLAMI). N/A
Recruiting NCT05353140 - LAAO Versus NOAC in Patients With AF and PCI N/A